If you have been wondering whether Centene is a beaten down bargain or a value trap, you are not alone and the numbers give us plenty to dig into.
The stock trades around $38.81 after a choppy run, down 2.1% over the last week but still up 9.7% over the past month, while longer term returns remain deeply negative with a 35.9% drop year to date.
Recent headlines have focused on Centene’s ongoing strategic repositioning in government sponsored healthcare and its efforts to streamline operations and sharpen its portfolio mix. At the same time, investors are weighing regulatory developments in Medicaid and Medicare Advantage, which continue to shape expectations for the company’s long term growth and risk profile.
